Anzeige
Meldung des Tages: Fusion im Wert von 1 Mrd. US-Dollar! Eine Royalty-Ausgliederung! Der Meeresboden wird neu bewertet

Biohaven News

Aktie
WKN:  A3DVH7 ISIN:  VGG1110E1079 US-Symbol:  BHVN Branche:  Biotechnologie Land:  USA
9,64 $
+0,44 $
+4,78%
8,2212 € 19:10:55 Uhr
Depot/Watchlist
Marktkapitalisierung *
957,79 Mio. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Biohaven News

19.03.26 - PR Newswire
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-​Activin Pathway Inhibitor, Completes Enrollment PR Newswire
02.03.26 - PR Newswire
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results PR Newswire
12.01.26 - PR Newswire
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference
Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare ...
07.01.26 - PR Newswire
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026
Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 PR Newswire
24.12.25 - PR Newswire
Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder
Biohaven Provides Update From Phase 2 Proof-​of-Concept Study with BHV-7000 in Major Depressive Disorder PR Newswire
11.12.25 - PR Newswire
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-​Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society ...
13.11.25 - PR Newswire
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately ...
12.11.25 - PR Newswire
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares PR Newswire
11.11.25 - PR Newswire
Biohaven Announces Proposed Public Offering of Common Shares
Biohaven Announces Proposed Public Offering of Common Shares PR Newswire
10.11.25 - PR Newswire
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments
Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments PR Newswire
04.11.25 - PR Newswire
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia
FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia PR Newswire
12.09.25 - PR Newswire
Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN
Biohaven Ltd. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN PR Newswire
11.09.25 - PR Newswire
BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit PR Newswire
09.09.25 - PR Newswire
Levi & Korsinsky Reminds Biohaven Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN
Levi & Korsinsky Reminds Biohaven Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 12, 2025 - BHVN PR Newswire
08.09.25 - PR Newswire
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm
BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
08.09.25 - PR Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN
Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers - BHVN PR Newswire
08.09.25 - PR Newswire
Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Biohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
08.09.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd.(BHVN) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Biohaven Ltd.(BHVN) Shareholders PR Newswire
06.09.25 - PR Newswire
BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit
BHVN Deadline: BHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud Lawsuit PR Newswire
06.09.25 - PR Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biohaven PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »